Zobrazeno 1 - 10
of 102
pro vyhledávání: '"Rao Koganty"'
Autor:
R. Rao Koganty, Teresa Gilewski, Maura N. Dickler, Clifford A. Hudis, Alan N. Houghton, K. Panageas, Sonal Bhuta, Larry Norton, Govind Ragupathi, Philip O. Livingston, Jeannette Chin-Eng, Shemeeakah Powell
Publikováno v:
Clinical Cancer Research. 13:2977-2985
Purpose: To determine the clinical toxicities and antibody response against sTn and tumor cells expressing sTn following immunization of high-risk breast cancer patients with clustered sTn-KLH [sTn(c)-KLH] conjugate plus QS-21.Experimental Design: Tw
Publikováno v:
Carbohydrate Research. 342:784-796
Structurally defined immunostimulatory adjuvants play important roles in the development of new generation vaccines. Here described are the syntheses of three monophosphoryl lipid A analogues (1-3) with different substitution at 3-O-position of the r
Autor:
R. Rao Koganty, Zi-Hua Jiang
Publikováno v:
Current Medicinal Chemistry. 10:1423-1439
A clear understanding of the mechanism of function of immune stimulatory adjuvants, which commonly accompany vaccines, is beginning to emerge. Recent investigations have demonstrated that Toll-like receptors (TLRs) are the critical link between the i
Autor:
Mimi V. Bach, Wladyslaw Budzynski, Mark J. Krantz, B. Michael Longenecker, Zi-Hua Jiang, R. Rao Koganty
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 12:2193-2196
Structurally well-defined immune stimulatory molecules are important components of new generation molecular vaccines. In this paper, the design and synthesis of two lipid A analogues containing an unnatural tri-lipid acyl group are described. In a to
Publikováno v:
Glycoconjugate Journal. 17:835-848
Synthetic oligosaccharide vaccines based on core STn (sialyl α2-6 GalNAc) carbohydrate epitopes are being evaluated by a number of biopharmaceutical firms as potential immunotherapeutics in the treatment of mucin-expressing adenocarcinomas. The STn
Autor:
R. Rao Koganty, Malcolm S. Mitchell, G D MacLean, Mark A. Reddish, B. Michael Longenecker, June Kan-Mitchell, Vicky Jones
Publikováno v:
International Journal of Cancer. 76:817-823
Sixteen metastatic breast cancer patients were immunized with a low dose (5 micrograms) of a 16 amino acid MUC1 peptide (GVTSAPDTRPAPGSTA) conjugated to KLH (BP16-KLH) plus DETOX adjuvant and evaluated for antibody titers against MUC1 peptide and KLH
Autor:
M J Krantz, Wladyslaw Budzynski, B. M. Longenecker, J. A. Rogers, R. Rao Koganty, H. H. Guan, Mark A. Reddish, John Samuel
Publikováno v:
Bioconjugate Chemistry. 9:451-458
Synthetic human MUC1 peptides are important candidates for therapeutic cancer vaccines. To explore whether a human MUC1 peptide BP25 (STAPPAHGVTSAPDTRPAPGSTAPP) can be rendered immunogenic by incorporation in liposomes, the effects of physical associ
Autor:
John Samuel, R. Rao Koganty, Wladyslaw Budzynski, B. M. Longenecker, G L Zimmermann, Mark A. Reddish, M J Krantz, Lei Ding
Publikováno v:
International Journal of Cancer. 75:295-302
A human MUC1-transfected mouse mammary adenocarcinoma cell line (GZHI) was used to develop both subcutaneous and intravenous tumor models. A vaccine formulation comprised of a 24 mer (human MUC1) synthetic peptide encapsulated with monophosphoryl lip
Publikováno v:
Glycoconjugate Journal. 15:217-221
STn (NeuAcalpha2 --> 6GalNAc alpha-O-Ser/Thr) is a carbohydrate epitope overexpressed in various human carcinomas. Clinical trials are underway using synthetic STn or STn trimeric glycopeptides [STn, cluster; STn(c)] conjugated with keyhole limpet he
Autor:
R. Rao Koganty, Dongxu Qiu
Publikováno v:
Tetrahedron Letters. 38:961-964
Trichloroacetimidate at 1 and 3 position of 4,6-benzylidenyl N-acetylgalactosamine serves as a leaving group for glycosylation and a selective and acid sensitive protecting group respectively. This versatile donor, while forming exclusive α-glycosid